| Excerpt | Reference |
|---|
| "Autoimmune hepatitis is a heterogeneous disorder that typically responds to glucocorticoids with or without azathioprine." | ( Burak, KW; Swain, MG; Urbanski, SJ, 1998) |
| "Autoimmune hepatitis is a chronic inflammatory liver disorder of unknown etiology associated with serum autoantibodies and hypergammaglobulinemia." | ( Torres, EA; Viruet, EJ, 1998) |
| "Autoimmune hepatitis is a form of chronic liver disease characterized by progressive hepatocellular inflammation, which usually responds to treatment with corticosteroids." | ( Fernandes, NF; Fong, TL; Redeker, AG; Vierling, JM; Villamil, FG, 1999) |
| "Minocycline-induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis." | ( Bayati, N; Goldstein, NS; Gordon, SC; Silverman, AL, 2000) |
| "Autoimmune hepatitis is one of the causes of chronic progressive liver disease in childhood." | ( Gürakan, F; Koçak, N; Ozen, H; Saltik, IN; Yüce, A, 2001) |
| "Autoimmune hepatitis is a chronic inflammatory liver disease that responds well to prednisone alone or in combination with azathioprine." | ( Luxon, BA, 2003) |
| "Autoimmune hepatitis is a rare chronic disease that mainly affects young women and may influence fertility and pregnancy in these patients." | ( Blickstein, I; Kruchkovich, J, 2003) |
| "Autoimmune hepatitis is a disorder of unknown aetiology in which progressive destruction of the hepatic parenchyma occurs, often progressing to cirrhosis." | ( Ertekin, V; Selimoglu, MA, 2003) |
| "In India, autoimmune hepatitis is uncommon and usually presents with chronic hepatitis or cirrhosis, acute hepatitis being less common." | ( Alexander, G; Baba, CS; Choudhuri, G; Somani, SK, 2005) |
| "Autoimmune hepatitis is a disorder of unknown aetiology." | ( Besson, C; Buffet, C; Dhalluin-Venier, V; Dimet, S; Tchernia, G; Thirot-Bibault, A, 2006) |
| "The treatment of autoimmune hepatitis is evolving as the pathogenic pathways that underlie the disease are defined, new immunosuppressive agents are tested, and site-specific molecular interventions become feasible." | ( Czaja, AJ; Montano Loza, AJ, 2007) |
| "Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroid-sparing effect." | ( Gershwin, ME; Ishibashi, H; Komori, A; Shimoda, S, 2007) |
| "Autoimmune hepatitis is a generally progressive, chronic hepatitis of unknown cause but with an autoimmune background." | ( Aresti, S; Cortés, MA; Cuadrado, A; Gómez-Ortega, JM; Salcines, JR, 2009) |
| "Autoimmune hepatitis is characterized by inflammatory liver histology, circulating nonorgan-specific autoantibodies, and increased levels of immunoglobulin G, in the absence of a known etiology." | ( Chang, MH; Fujisawa, T; González-Peralta, RP; Heller, S; Jara, P; Kelly, D; Mieli-Vergani, G; Mohan, N; Murray, KF; Shah, U; Vergani, D, 2009) |
| "Autoimmune hepatitis is a chronic liver disease of unknown aetiology characterized by interface hepatitis, hypergammaglobulinaemia and circulating autoantibodies." | ( Cassani, F; Granito, A; Lenzi, M; Muratori, L; Muratori, P; Pappas, G, 2010) |
| "Autoimmune hepatitis is a chronic inflammatory disease of the liver with a dismal prognosis when left untreated." | ( Strassburg, CP, 2010) |
| "Autoimmune hepatitis is characterized by hepatocellular inflammation often progressing to cirrhosis." | ( Brown, KA; Huang, MA; Schreibman, IR; Sharzehi, K, 2010) |
| "Autoimmune hepatitis is exquisitely responsive to immunosuppression but treatment must be started as soon as possible to achieve full remission and halt progression of liver disease." | ( Mieli-Vergani, G; Vergani, D, 2011) |
| "Autoimmune hepatitis is a rare disease." | ( Adam, P; Klein, R; Lauer, U; Minkley, L, 2011) |
| "Autoimmune hepatitis is an immune-mediated disease targeting hepatocytes." | ( Basevitz, A; Duek, G; Malnick, S; Melzer, E, 2012) |
| "Autoimmune hepatitis is a relatively rare disease that may lead to rapidly progressing liver cirrhosis and even fulminant liver failure, if diagnosis and treatment is delayed or ineffective." | ( Larsen, FS; Ytting, H, 2012) |
| "Drug-induced autoimmune hepatitis is an acute and potentially severe side effect, particularly often reported after the long-term use of minocycline." | ( Aldenhoven, M; Avis, WA; van Enk, JG, 2013) |
| "Autoimmune hepatitis is chronic liver disease with two subtypes, type 1 with anti nuclear or smooth muscle antibodies and type 2 with LKM1 or LC1 antibodies, and both with hypergammaglobulinemia and typical histology." | ( Färkkilä, M, 2013) |
| "Autoimmune hepatitis is a rare disease with high clinical variability." | ( Brissos, J; Cabral, J; Carrusca, C; Correia, M, 2014) |
| "Autoimmune hepatitis is a chronic immune-mediated liver injury, frequently associated with progression to end-stage liver disease if untreated." | ( Adams, DH; Corrigan, M; Hirschfield, GM; Oo, YH, 2015) |
| "Autoimmune hepatitis is characterized by autoantibodies, hypergammaglobulinemia, and interface hepatitis on histological examination." | ( Czaja, AJ, 2016) |
| "Autoimmune hepatitis is characterized, in part, by the pathways involving cysteinyl-leukotriene metabolites of arachidonic acid, the dynamics of which remain unclear." | ( Hua, D; Li, L; Lou, Y; Mangan, CJ; Qi, L; Su, K; Tao, J; Wang, Q, 2016) |
| "Autoimmune hepatitis is a chronic inflammatory liver disease." | ( Hartl, J; Lohse, AW; Sebode, M; Vergani, D, 2018) |
| "Autoimmune hepatitis is a rare chronic inflammatory liver disease, affecting all ages, characterised by elevated transaminase and immunoglobulin G levels, positive autoantibodies, interface hepatitis at liver histology and good response to immunosuppressive treatment." | ( Mieli-Vergani, G; Terziroli Beretta-Piccoli, B; Vergani, D, 2017) |
| "Autoimmune hepatitis is a chronic immune-mediated liver injury caused by dysregulated immune response to liver antigens." | ( Fallahi, G; Farahmand, F; Khodadad, A; Motamed, F; Najafi, M; Rezaei, N; Sadr, M; Shabani, M; Shafioyoun, A; Varzaneh, FN; Yousefi, A; Zare Bidoki, A, 2019) |
| "Autoimmune hepatitis is a corticosteroid-responsive liver disease arising consequent to immunogenetic and environmental risk factors." | ( Gleeson, D; Heneghan, M; Hirschfield, GM; Hubscher, SG; Trivedi, PJ, 2019) |
| "Autoimmune hepatitis is a rare cause of hepatitis in HIV-infected individuals; however, this condition has been increasingly reported over the past few years." | ( Avihingsanon, A; Chaiteerakij, R; Sanpawat, A; Treeprasertsuk, S, 2019) |
| "Autoimmune hepatitis is widely assumed by health-care professionals to be a disease that is easily controlled through the use of corticosteroids and immunosuppressants but recent studies in the UK indicate highly variable treatment regimens and often unsatisfactory treatment outcomes, such as dependence on long-term high-dose steroids and ongoing need for liver transplantation in some cases." | ( Aspinall, RJ; Chapman, RW; Heneghan, M; Trivedi, P; Wright, G, 2019) |
| "Autoimmune hepatitis is a rare and chronic liver disease that is characterised by increased serum transaminases and immunoglobulin G, inflammatory liver histology and presence of circulating autoantibodies." | ( Gevers, TJ; Pape, S; Schramm, C, 2019) |
| "Autoimmune hepatitis is a rare but chronic autoimmune-mediated liver disease." | ( Böttler, T; Thimme, R; Vogelbacher, L, 2022) |
| "Autoimmune hepatitis is an interface hepatitis characterized by the progressive destruction of the liver parenchyma, the cause of which is still obscure." | ( Bi, K; Chen, J; Diao, H; Jiang, J; Li, X; Lin, C; Zeng, P; Zhang, X, 2022) |
| "Autoimmune hepatitis is a chronic inflammatory disease of the liver." | ( Londoño, MC; Olivas, I; Rodríguez-Tajes, S, 2022) |
| "Autoimmune hepatitis is an autoimmune disease with increasing occurrence worldwide." | ( Fan, L; Li, L; Li, Q; Liu, Q; Maihemuti, N; Tang, S; Xiao, L; Zhang, F; Zhang, L; Zhang, S, 2022) |
| "Autoimmune hepatitis is mainly the disease of females and a potentially treatable cause of chronic liver disease." | ( Chaitanya, V; Jagtap, AB; Lall, B; Porwal, YC; S, C, 2023) |
| "Autoimmune hepatitis is a common cause of acute liver failure." | ( Bass, N; Durkalski, V; Enke, T; Ganger, D; Larson, A; Lee, W; Livingston, S; Rakela, J; Reuben, A; Rule, J; Stravitz, T; Sussman, N; Tujios, S, 2023) |
| "Autoimmune hepatitis is a serious hepatic disorder with unknown nosogenesis, and natural products have been deemed to be one of the most significant sources of new drugs against this disease." | ( Chen, G; Feng, H; Guo, J; Hao, X; Hou, Z; Qi, C; Shi, Z; Song, F; Sun, L; Tan, X; Wu, M; Xie, P; Zhang, Y; Zhao, X, 2023) |
| Excerpt | Reference |
|---|
| "Our data show that symptoms of autoimmune hepatitis, which are responsive to the classical treatment for this condition, can appear in liver-transplant patients while they are on anti-rejection immunosuppression." | ( Davies, ET; Donaldson, PT; Hadzić, N; Heaton, ND; Kerkar, N; Mieli-Vergani, G; Portmann, B; Rela, M; Vergani, D, 1998) |
| "Recurrence of autoimmune hepatitis after liver transplantation is not rare, but there is little information about its time of onset, risk factors, response to treatment and prognosis." | ( Casanovas, T; Clemente, G; Cuervas-Mons, V; de la Mata, M; Fabrega, E; Fraga, E; Prados, E; Prieto, M; Rimola, A; Vicente, E, 1998) |
| "The conventional treatment of autoimmune hepatitis (AIH) with prednisone and azathioprine induces remission in most cases but is often associated with poorly tolerated side effects." | ( Bernard, O; Debray, D; Girardet, JP; Maggiore, G; Mallet, E, 1999) |
| "most patients with autoimmune hepatitis require long-term treatment, but up to 80% of them will develop collateral effects." | ( Caunedo Alvarez, A; Cifuentes Mimoso, C; Herrerías Gutiérrez, J; Jiménez-Sáenz, M; Piñar Moreno, A; Rebollo Bernárdez, J; Salas Herrero, E, 1999) |
| "We report one case of autoimmune hepatitis following treatment with minocycline for acne, in a 25-year-old woman." | ( Andréjak, M; Barbieux, D; Dadamessi, I; Duché, A; Ducroix, JP; Leduc, I; Sevestre, H; Tiev, K, 1999) |
| "Thirteen patients with intractable autoimmune hepatitis who had an incomplete or arrested response to conventional prednisolone therapy, or who relapsed during prednisolone maintenance therapy were additionally administered 50 or 100 mg/day of azathioprine in combination with prednisolone." | ( Fujiwara, A; Miyake, Y; Miyashita, M; Nishimura, M; Sakaguchi, K; Takenami, T; Terao, M; Tsuji, T, 2001) |
| "The patient was diagnosed with autoimmune hepatitis and responded well to treatment with immunosuppressive drugs." | ( Belda Abad, G; Correa Estañ, JA; Hostalet Robles, F; Muñoz Bertrán, E; Muñoz Ramírez, E; Rosa Salazar, V, 2002) |
| "Relapse of type 1 autoimmune hepatitis after drug withdrawal may relate to incomplete histological improvement during corticosteroid therapy and/or persistence of pathogenic mechanisms." | ( Carpenter, HA; Czaja, AJ, 2003) |
| "International autoimmune hepatitis (AIH) score showed definite AIH before treatment, but autoantibodies could not make a differential diagnosis of AIH and SLE-associated hepatitis." | ( Harada, Y; Hirohata, S; Ishii, M; Iwai, M; Mori, T; Muramatsu, A; Nakashima, T; Okanoue, T; Tanaka, S, 2003) |
| "TPMT activity in patients with autoimmune hepatitis displays a similar distribution to that reported in other populations (approximately 1% of patients have low levels and 9% have intermediate levels) and it does not depend on the age, gender or simultaneous azathioprine treatment." | ( Cara, C; Gisbert, JP; González-Guijarro, L; Moreno-Otero, R; Pajares, JM, 2003) |
| "The chronic hepatitis C-autoimmune hepatitis (AIH) overlap syndrome has been described in the literature, but to date appropriate therapy remains controversial." | ( Dries, V; Goeser, T; Kasper, HU; Petersen-Benz, C, 2004) |
| "The use of corticosteroids in autoimmune hepatitis is an established therapy." | ( Aparicio Pages, MN; de Boer, NK; de Boer, SY; Derijks, LJ; Mulder, CJ; van Nieuwkerk, CM, 2005) |
| "In elderly Italian patients, autoimmune hepatitis has typical serological and genetic characteristics, is more frequently asymptomatic, although prognosis and response to therapy is similar to that of younger patients." | ( Bianchi, FB; Cassani, F; Ferri, S; Granito, A; Lenzi, M; Muratori, L; Muratori, P; Pappas, G, 2005) |
| "Conventional treatment of autoimmune hepatitis consists of either prednisone alone or in combination with azathioprine." | ( Bain, VG; Chatur, N; Deschenes, M; Ghent, CN; Heathcote, EJ; Lee, SS; Lilly, LB; Ma, MM; Marotta, PJ; Ramji, A; Steinbrecher, UP; Yoshida, EM, 2005) |
| "The prognosis of type 1 autoimmune hepatitis on adequate immunosuppressive treatment improves when the serum alanine aminotransferase level persists at < or = 40 IU/L." | ( Ikeda, H; Iwasaki, Y; Kobashi, H; Makino, Y; Miyake, Y; Okamaoto, R; Sakaguchi, K; Sakai, N; Shiratori, Y; Takagi, S; Takaguchi, K; Terada, R, 2005) |
| "This case is the first report of an autoimmune hepatitis associated with ezetimibe therapy." | ( van Heyningen, C, 2005) |
| "Whether primary biliary cirrhosis (PBC)-autoimmune hepatitis (AIH) overlap syndrome requires immunosuppressive therapy in addition to ursodeoxycholic acid (UDCA) is a controversial issue." | ( Chazouillères, O; Poupon, R; Rosmorduc, O; Serfaty, L; Wendum, D, 2006) |
| "In > 80% of patients with autoimmune hepatitis, steroid therapy alone or in combination with azathioprine results in disease remission." | ( Al-Chalabi, T; Heneghan, MA; McFarlane, IG, 2006) |
| "De novo autoimmune hepatitis should be considered in differential diagnosis along with rejection in liver transplanted patients developing graft dysfunction while on treatment with interferon." | ( Andreone, P; Berardi, S; Bernardi, M; Biselli, M; Bontadini, A; D'Errico, A; Gramenzi, A; Grazi, G; Lenzi, M; Lodato, F; Mazzella, G; Morelli, MC; Pinna, AD; Piscaglia, F; Sama, C; Tamè, MR, 2007) |
| "Although the prognosis of type 1 autoimmune hepatitis is generally good with immunosuppressive treatment, the disease progresses in some patients despite the treatment." | ( Ikeda, H; Iwasaki, Y; Kobashi, H; Makino, Y; Miyake, Y; Okamaoto, R; Sakaguchi, K; Shiratori, Y; Takaguchi, K; Terada, R, 2006) |
| "The treatment of autoimmune hepatitis is evolving as the pathogenic pathways that underlie the disease are defined, new immunosuppressive agents are tested, and site-specific molecular interventions become feasible." | ( Czaja, AJ; Montano Loza, AJ, 2007) |
| "The immunosuppressive treatment for autoimmune hepatitis (AIH) patients is prednisone and azathioprine." | ( Adams, A; Bonacini, M; Bzowej, NH; Frederick, RT; Gish, RG; Inductivo-Yu, I; Wakil, A, 2007) |
| "Standard treatment for autoimmune hepatitis (AIH) involves immune suppression by using prednisone alone or in combination with azathioprine (AZA)." | ( Fuchs, M; Hlivko, JT; Luketic, VA; Sanyal, AJ; Shiffman, ML; Sterling, RK; Stravitz, RT, 2008) |
| "Untreated patients with autoimmune hepatitis (AIH) who present with aspartate aminotransferase (AST) levels that are more than 5-fold greater than the upper limit of normal (UPLN) have a mortality rate of up to 80%." | ( Al-Chalabi, T; Heneghan, MA; McFarlane, IG; Portmann, BC; Underhill, JA, 2008) |
| "In patients with autoimmune hepatitis, efficient immunosuppressive therapy is essential to avoid progression to cirrhosis." | ( Adams, DH; Boecher, W; Buggisch, P; Denzer, U; Galle, PR; Hennes, EM; Kanzler, S; Lohse, AW; Oo, YH; Schramm, C; Schuchmann, M; Wiegard, C, 2008) |
| "The role of the immune response in autoimmune hepatitis has not been studied before and after prednisone and azathioprine treatment." | ( Bluth, MH; Chice, S; Durkin, HG; Kohlhoff, S; Norowitz, KB; Nowakowski, M; Silverberg, JI; Smith-Norowitz, TA, 2009) |
| "We describe the occurrence of autoimmune hepatitis in a patient treated with adalimumab, a fully human IgG antibody against tumor necrosis factor, for psoriatic arthritis." | ( Adar, T; Mizrahi, M; Pappo, O; Scheiman-Elazary, A; Shibolet, O, 2010) |
| "Patients with autoimmune hepatitis (AIH) frequently have liver failure (LF) at the time of diagnosis; their response to immunosuppressive therapy has not been thoroughly analyzed." | ( Alvarez, F; Ciocca, ME; Cuarterolo, ML; de Dávila, MT; López, SI, 2011) |
| "In patients with autoimmune hepatitis who were intolerant to conventional therapy, MMF was well tolerated, with 88% of patients maintained in remission." | ( Brown, KA; Huang, MA; Schreibman, IR; Sharzehi, K, 2010) |
| "Standard therapy for autoimmune hepatitis (AIH) is corticosteroids with or without azathioprine." | ( Dalekos, GN; Gatselis, N; Papadamou, G; Rigopoulou, EI; Zachou, K, 2011) |
| "Treatment failure occurs in 20% of autoimmune hepatitis patients on prednisolone and azathioprine (AZA)." | ( Baven-Pronk, AM; Beuers, UH; Bouma, G; Brouwer, JT; Coenraad, MJ; de Man, RA; den Ouden, J; Drenth, JP; Koek, GH; Lamers, MM; van Buuren, HR; van den Berg, AP; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, CM, 2011) |
| "We describe a case of a young man with autoimmune hepatitis (AIH) following Epstein-Barr virus (EBV) infection, in whom a long follow-up showed favourable outcome with complete clinical recovery and failure to relapse after cessation of immunosuppressive therapy." | ( Cabibi, D, 2008) |
| "Current treatment strategies in autoimmune hepatitis (AIH) include long-term treatment with corticosteroids and/or azathioprine." | ( Beuers, U; Bouma, G; Brouwer, JT; Coenraad, MJ; de Man, RA; den Ouden, JW; Drenth, JP; Guichelaar, MM; Koek, GH; Mulder, CJ; van Buuren, HR; van Erpecum, KJ; van Gerven, NM; van Hoek, B; van Nieuwkerk, KM; Verdonk, RC; Verwer, BJ; Witte, BI, 2013) |
| "The conventional treatment of autoimmune hepatitis (AIH) in children, which includes prednisone alone or in combination with azathioprine, induces remission in most cases but is often associated with poorly tolerated side effects." | ( Franulović, OZ; Kuna, AT; Lesar, T; Morić, BV; Rajacić, N, 2012) |
| "This type of autoimmune hepatitis can be differentiated from 'classic' autoimmune hepatitis by the patient's quick recovery after stopping the inducing drug and no relapse of the condition after the discontinuation of glucocorticoid therapy." | ( Aldenhoven, M; Avis, WA; van Enk, JG, 2013) |
| "Ten percent of patients with autoimmune hepatitis (AIH) are nonresponsive or intolerant to thiopurine therapy." | ( Bouma, G; de Boer, NK; de Boer, YS; Mulder, CJ; van Gerven, NM; van Nieuwkerk, CM, 2013) |
| "Most patients with autoimmune hepatitis (AIH) initially respond to treatment with corticosteroids but often experience a relapse after treatment is withdrawn." | ( Aoki, N; Chiba, T; Ikeda, A; Iwamoto, S; Kido, M; Maruoka, R; Nishiura, H; Watanabe, N, 2013) |
| "Although most patients with autoimmune hepatitis (AIH) respond to treatment with prednisone and⁄or azathioprine, some patients are intolerant or refractory to standard therapy." | ( Aspinall, AI; Burak, KW; Coffin, CS; Lee, SS; Myers, RP; Santodomingo-Garzon, T; Santodomino-Garzon, T; Swain, MG; Urbanski, SJ, 2013) |
| "Cholestatic findings in autoimmune hepatitis influence the response to immunosuppressive therapy." | ( Czaja, AJ, 2013) |
| "Acute autoimmune hepatitis was induced by Con A (20 mg/kg) in Balb/C mice; ethyl pyruvate (40 mg/kg and 80 mg/kg) was administrated 1h prior to the Con A injection." | ( Chen, K; Cheng, P; Dai, W; Guo, C; Lin, C; Lu, J; Shen, M; Wang, C; Wang, F; Xu, L; Zhang, Y; Zhou, Y, 2014) |
| "We treated a woman with marker-negative autoimmune hepatitis associated with the glucagon-like peptide 1 agonist liraglutide." | ( Kern, E; Rinella, ME; VanWagner, LB; Yang, GY, 2014) |
| "Overlapping features between autoimmune hepatitis (AIH) and cholestatic disorders (primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), or indeterminate cholestasis), so-called overlap syndromes, usually have a progressive course toward cirrhosis and liver failure without adequate treatment." | ( Bunchorntavakul, C; Reddy, KR, 2015) |
| "He was diagnosed with autoimmune hepatitis, polymyositis and Sjögren's syndrome and received combined antiretroviral therapy (cART); however, the laboratory abnormalities persisted." | ( Higuchi, M; Kaieda, T; Kaku, Y; Kodama, S; Minami, R; Miyamura, T; Nakamura, A; Nakamura, M; Suematsu, E; Takahama, S; Yamamoto, M, 2015) |
| "Not all patients with autoimmune hepatitis (AIH) respond to standard medical therapy with corticosteroids and azathioprine." | ( Larsen, FS; Ytting, H, 2015) |
| "The patient was diagnosed to have autoimmune hepatitis type-1 and treated with injection methylprednisolone pulse (500 mg/day for 3 days) and maintained on oral steroids and azathioprine 100 mg." | ( Bhardwaj, M; Sunder, S; Venkataramanan, K; Verma, H, 2015) |
| "(1) Standard treatment of autoimmune hepatitis in adults should be steroid based." | ( Gleeson, D, 2015) |
| "An 82-year-old woman with autoimmune hepatitis had been treated with 5 mg prednisolone (PSL) orally to maintain normal transaminase levels." | ( Asai, A; Fukunishi, S; Higuchi, K; Nakamura, K; Nishida, S; Ohama, H; Tsuda, Y; Yokohama, K, 2016) |
| "Therapy for autoimmune hepatitis has been prednisone based for decades; however, budesonide may be equally effective with fewer side effects." | ( Mohammad, S, 2016) |
| "Immune reconstitution related autoimmune hepatitis should be considered in the differential diagnosis of hepatitis in the HIV-infected patient on antiretroviral therapy." | ( Andersson, M; Murunga, E; Rensburg, Cv, 2016) |
| "The long-term outcomes of patients with autoimmune hepatitis (AIH) given the immunosuppressive treatment are considered to be preferable." | ( Guo, LP; Li, SQ; Li, YN; Ma, H; Qian, YQ; Wang, BM; Zhang, J; Zhou, L, 2016) |
| "Many patients with autoimmune hepatitis (AIH) develop steroid-specific side effects or require doses of steroids that are unacceptable for long-term treatment." | ( Ehlken, H; Hartl, J; Liebscher, T; Lohse, AW; Pannicke, N; Peiseler, M; Schramm, C; Sebode, M; Weiler-Normann, C; Zenouzi, R, 2018) |
| "Adult studies of autoimmune hepatitis (AIH) have shown that the model of end-stage liver disease is associated with resistance to first-line treatment." | ( Ahmed, N; Alvarez, F; Critch, J; Jimenez-Rivera, C; Kamath, BM; Kim, J; Ling, SC; Schreiber, RA; Yap, J; Zizzo, AN, 2017) |
| "The standard treatment for autoimmune hepatitis (AIH) is predniso(lo)ne for remission induction, tapered and followed by azathioprine, which effectively controls the disease in the majority of patients." | ( Eriksen, PL; Grønbaek, H; Jessen, N; Kreutzfeldt, M; Thorsen, K; Vang, S; Vilstrup, H, 2017) |
| "Ten percent to 20% of children with autoimmune hepatitis (AIH) require second-line therapy to achieve remission." | ( Kamath, BM; Shah, PS; Valentino, PL; Zizzo, AN, 2017) |
| "Beyond available guidelines, therapy of autoimmune hepatitis (AIH) shows wide variation among physicians." | ( Efe, C; Kav, T; Ozaslan, E; Purnak, T; Wahlin, S, 2017) |
| "The gold-standard treatment for autoimmune hepatitis (AIH) is a prednisone/azathioprine combination." | ( Azeredo-da-Silva, ALF; Costabeber, AM; De Lemos-Bonotto, M; Mattos, AA; Valle-Tovo, C, 2018) |
| "Although autoimmune hepatitis (AIH) can be treated with corticosteroid-based first-line therapy, incomplete remission is associated with progressive liver fibrosis." | ( Baumann, U; Diestelhorst, J; Falk, CS; Jaeckel, E; Jonigk, D; Junge, N; Manns, MP; Schlue, J; Taubert, R, 2018) |
| "Treatment paradigms in autoimmune hepatitis (AIH) have remained largely unchanged for decades." | ( Bigirumurame, T; Dyson, JK; Heneghan, MA; Hirschfield, GM; Jones, DEJ; Kendrick, S; Lohse, AW; Oo, YH; Wong, LL, 2018) |
| "The United Kingdom Autoimmune Hepatitis (UK-AIH) study was established to evaluate current treatment practice and outcomes, determine the unmet needs of patients, and develop and implement improved treatment approaches." | ( Bigirumurame, T; Dyson, JK; Heneghan, MA; Hirschfield, GM; Jones, DEJ; Kendrick, S; Lohse, AW; Oo, YH; Wong, LL, 2018) |
| "Data on rescue treatment of autoimmune hepatitis in patients that fail standard treatment are sparse." | ( Almer, S; Friis-Liby, IL; Giannakopoulos, G; Nyhlin, N; Sangfelt, P; Verbaan, H, 2019) |
| "Approximately one of two patients with autoimmune hepatitis that fail standard treatment benefit from long-term maintenance with mycophenolate mofetil, especially those with previous intolerance to thiopurines, where mycophenolate mofetil is effective in two thirds." | ( Almer, S; Friis-Liby, IL; Giannakopoulos, G; Nyhlin, N; Sangfelt, P; Verbaan, H, 2019) |
| "Development of autoimmune hepatitis (AIH) has been sporadically reported in patients with multiple sclerosis (MS) either concurrently or after treatment with immunomodulatory drugs, including interferon-beta (IFN-β) and steroids." | ( Arvaniti, P; Dalekos, GN; Gyftaki, S; Hadjigeorgiou, G; Koukoulis, GK; Rigopoulou, EI; Tsimourtou, V, 2019) |
| "Patients with autoimmune hepatitis (AIH) commonly receive induction therapy with predniso(lo)ne followed by maintenance therapy with azathioprine." | ( Belias, M; Bouma, G; Drenth, JPH; Gevers, TJG; Hartl, J; Heneghan, MA; Jaeckel, E; Lohse, AW; Manns, MP; Mustafajev, IF; Pape, S; Papp, M; Schramm, C; Stickel, F; Taubert, R; van Hoek, B; van Nieuwkerk, CMJ; Vrolijk, JM, 2019) |
| "Initial treatment of autoimmune hepatitis (AIH) with prednisolone ± azathioprine is based on randomised controlled trials." | ( Gleeson, D; Harrison, L, 2019) |
| "First-line treatment for autoimmune hepatitis (AIH) typically includes corticosteroids in combination with azathioprine." | ( Levy, C; Santiago, P; Schwartz, I; Tamariz, L, 2019) |
| "Steroids are the standard therapy for autoimmune hepatitis (AIH) but the long-lasting administration is hampered by severe side effects." | ( Bagnati, R; Baldan, S; Barisani, D; Biffi, S; Bigini, P; Casarin, E; Christen, U; De Simoni, MG; Fumagalli, S; Gimondi, S; Hintermann, E; Invernizzi, P; Messmer, M; Morpurgo, M; Passoni, A; Rossi, A; Russo, L; Salmona, M; Talamini, L; Toffanin, C; Tondello, C; Violatto, MB, 2019) |
| "Therapy for autoimmune hepatitis (AIH) consists of steroid induction therapy, followed by maintenance therapy with azathioprine." | ( Drenth, JPH; Mertens, C; Nevens, F; Pape, S; Tjwa, ETTL; Verslype, C, 2020) |
| "Fibrosis progression in autoimmune hepatitis can be attenuated by immunosuppressive treatment; however, some patients progress despite therapy." | ( Großhennig, A; Kirstein, MM; Manns, MP; Marhenke, S; Mederacke, I; Mederacke, YS; Metzler, F; Vogel, A, 2020) |
| "Guidelines regarding treatment for autoimmune hepatitis (AIH) favour two strategies for azathioprine (AZA) introduction: concurrent with steroids at induction or delayed by 2-4 weeks." | ( Bouma, G; Drenth, JPH; Efe, C; Gevers, TJG; Hartl, J; Heneghan, MA; Jaeckel, E; Kahraman, A; Kessener, DJN; Lohse, AW; Manns, MP; Nevens, F; Ozaslan, E; Pape, S; Papp, M; Purnak, T; Schramm, C; Sipeki, N; Stickel, F; Taubert, R; van Hoek, B; van Nieuwkerk, CMJ; Vrolijk, JM; Wedemeyer, H, 2020) |
| "Without treatment, autoimmune hepatitis (AIH) often leads to cirrhosis, liver failure and, in some cases, death." | ( Chen, H; Hao, H; Hao, J; Hou, T; Li, Z; Liu, Y, 2020) |
| "Although standard treatment for autoimmune hepatitis (AIH) comprises prednisolone (PSL) and azathioprine (AZA), some patients are intolerant to or do not respond to PSL and/or AZA." | ( Abe, K; Aiso, M; Aoyagi, H; Arizumi, T; Asaoka, Y; Isono, A; Kodashima, S; Matsumoto, K; Miki, A; Miura, R; Tachizawa, N; Tanaka, A; Yagi, M; Yamamoto, T, 2021) |
| "A chronic liver disease named autoimmune hepatitis (AIH) will carry elevated levels of inflammatory cytokines, but there is currently no effective treatment to cure it." | ( Cai, T; Chen, D; Chen, Y; Lin, Y; Wang, X; Xia, D; Xu, L; Yu, S; Zhu, K; Zhu, L, 2022) |
| "However, the diagnosis and treatment of autoimmune hepatitis (AIH) overlapping with either GD or chronic hepatitis B are challenging." | ( Brigstock, DR; Cui, S; Gao, R; Zhang, W; Zheng, M, 2022) |
| "Currently, the standard therapy for autoimmune hepatitis (AIH) consists of a combination of prednisolone and azathioprine." | ( Bakker, SF; Bartelink, M; Beuers, UHW; Biewenga, M; de Boer, YS; de Jonge, HJM; Drenth, JPH; Gevers, TJG; Gisbertz, IAM; Guichelaar, MMJ; Levens, AD; Pape, S; Pronk, MAMCB; Sebib Korkmaz, K; Sijtsma, MGM; Snijders, RJALM; Soufidi, K; Stoelinga, AEC; van den Berg, AP; van den Brand, FF; van der Meer, AJ; van Gerven, NMF; van Hoek, B; Vanwolleghem, T; Verdonk, RC; Verwer, BJ; Vrolijk, JM, 2022) |
| "Currently, the standard therapy for autoimmune hepatitis (AIH) consists of a combination of prednisolone and azathioprine." | ( Bakker, SF; Bartelink, M; Beuers, UHW; Biewenga, M; de Boer, YS; de Jonge, HJM; Drenth, JPH; Gevers, TJG; Gisbertz, IAM; Guichelaar, MMJ; Levens, AD; Pape, S; Pronk, MAMCB; Sebib Korkmaz, K; Sijtsma, MGM; Snijders, RJALM; Soufidi, K; Stoelinga, AEC; van den Berg, AP; van den Brand, FF; van der Meer, AJ; van Gerven, NMF; van Hoek, B; Vanwolleghem, T; Verdonk, RC; Verwer, BJ; Vrolijk, JM, 2022) |
| "In children with autoimmune hepatitis, uncertainties include outcomes associated with type 2 hepatitis, the possibility of and criteria for attempting withdrawal of treatment, and long-term outcomes." | ( Ballot, E; Bernard, O; Jacquemin, E; Johanet, C; Maggiore, G; Mosca, A, 2023) |
| "In children with autoimmune hepatitis, there are conflicting reports on the differences in outcome between type 1 and type 2 hepatitis, and on the possibility of treatment withdrawal, before which liver histology is required; data concerning >10-year overall and native liver survival rates are limited." | ( Ballot, E; Bernard, O; Jacquemin, E; Johanet, C; Maggiore, G; Mosca, A, 2023) |
| "The Swiss Autoimmune Hepatitis Cohort Study is a nationwide registry, initiated in 2017, that collects retrospective and prospective clinical data and biological samples from patients of all ages with autoimmune hepatitis treated at Swiss hepatology centres." | ( Becker, B; Bernsmeier, C; Böhm, S; Braegger, C; Bresson-Hadni, S; Cerny, A; Cremer, M; De Gottardi, A; Di Bartolomeo, C; Filipowicz Sinnreich, M; Furlano, R; Galante, A; Heyland, K; Kremer, AE; Limoni, C; Ludz, C; McLin, V; Mertens, J; Mieli-Vergani, G; Müller, P; Nydegger, A; Posovszky, C; Righini-Grunder, F; Rock, N; Semela, D; Sokollik, C; Stirnimann, G; Terziroli Beretta-Piccoli, B; Vergani, D, 2023) |
| "The goal of autoimmune hepatitis treatment is to achieve clinical and biochemical remission, which is associated with significantly improved outcomes." | ( Goel, A; Kwo, P, 2024) |